- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 937936, 9 pages
Anti-Inflammatory Effects of Arsenic Trioxide Eluting Stents in a Porcine Coronary Model
1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China
3Department of Cardiology, Sichuan Provincial People’s Hospital, Chengdu 610072, China
4Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China
Received 8 November 2012; Accepted 26 December 2012
Academic Editor: George Perry
Copyright © 2013 Li Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. E. Sousa, M. A. Costa, A. G. M. R. Sousa et al., “Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries,” Circulation, vol. 107, no. 3, pp. 381–383, 2003.
- G. W. Stone, S. G. Ellis, D. A. Cox et al., “A Polymer-based, paclitaxel-eluting stent in patients with coronary artery disease,” The New England Journal of Medicine, vol. 350, no. 3, pp. 221–231, 2004.
- A. Kastrati, J. Mehilli, J. Pache et al., “Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents,” The New England Journal of Medicine, vol. 356, no. 10, pp. 1030–1039, 2007.
- B. Lagerqvist, S. K. James, U. Stenestrand, J. Lindbäck, T. Nilsson, and L. Wallentin, “Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden,” The New England Journal of Medicine, vol. 356, no. 10, pp. 1009–1019, 2007.
- W. H. Maisel, “Unanswered questions: drug-eluting stents and the risk of late thrombosis,” The New England Journal of Medicine, vol. 356, no. 10, pp. 981–984, 2007.
- A. Farb, D. K. Weber, F. D. Kolodgie, A. P. Burke, and R. Virmani, “Morphological predictors of restenosis after coronary stenting in humans,” Circulation, vol. 105, no. 25, pp. 2974–2980, 2002.
- J. I. Kotani, M. Awata, S. Nanto et al., “Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings,” Journal of the American College of Cardiology, vol. 47, no. 10, pp. 2108–2111, 2006.
- G. J. Wilson, G. Nakazawa, R. S. Schwartz et al., “Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries,” Circulation, vol. 120, no. 2, pp. 141–149, 2009.
- S. H. Hofma, W. J. van der Giessen, B. M. van Dalen et al., “Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation,” European Heart Journal, vol. 27, no. 2, pp. 166–170, 2006.
- A. V. Finn, M. Joner, G. Nakazawa et al., “Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization,” Circulation, vol. 115, no. 18, pp. 2435–2441, 2007.
- A. V. Finn, G. Nakazawa, M. Joner et al., “Vascular responses to drug eluting stents: importance of delayed healing,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 7, pp. 1500–1510, 2007.
- J. Ako, Y. Morino, Y. Honda et al., “Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis,” Journal of the American College of Cardiology, vol. 46, no. 6, pp. 1002–1005, 2005.
- M. Joner, A. V. Finn, A. Farb et al., “Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk,” Journal of the American College of Cardiology, vol. 48, no. 1, pp. 193–202, 2006.
- T. F. Lüscher, J. Steffel, F. R. Eberli et al., “Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications,” Circulation, vol. 115, no. 8, pp. 1051–1058, 2007.
- J. Ako, H. N. Bonneau, Y. Honda, and P. J. Fitzgerald, “Design criteria for the ideal drug-eluting stent,” The American Journal of Cardiology, vol. 100, no. 8, pp. S3–S9, 2007.
- P. Zhang, S. Y. Wang, and L. H. Hu, “Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide,” Chinese Journal of Hematology, vol. 17, pp. 58–60, 1996.
- G. Q. Chen, J. Zhu, X. G. Shi et al., “In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML- RARα/PML proteins,” Blood, vol. 88, no. 3, pp. 1052–1061, 1996.
- H. Pelicano, L. Feng, Y. Zhou et al., “Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism,” Journal of Biological Chemistry, vol. 278, no. 39, pp. 37832–37839, 2003.
- Y. H. Kang, M. J. Yi, M. J. Kim et al., “Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria,” Cancer Research, vol. 64, no. 24, pp. 8960–8967, 2004.
- Z. Diaz, M. Colombo, K. K. Mann et al., “Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines,” Blood, vol. 105, no. 3, pp. 1237–1245, 2005.
- M. Baumgartner, S. Sturlan, E. Roth, B. Wessner, and T. Bachleitner-Hofmann, “Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells,” International Journal of Cancer, vol. 112, no. 4, pp. 707–712, 2004.
- X. H. Zhu, Y. L. Shen, Y. K. Jing et al., “Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations,” Journal of the National Cancer Institute, vol. 91, no. 9, pp. 772–778, 1999.
- W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman, “Mechanisms of action of arsenic trioxide,” Cancer Research, vol. 62, no. 14, pp. 3893–3903, 2002.
- G. J. Roboz, S. Dias, G. Lam et al., “Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis,” Blood, vol. 96, no. 4, pp. 1525–1530, 2000.
- W. Yang, J. B. Ge, H. L. Liu et al., “Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model,” Cardiovascular Research, vol. 72, no. 3, pp. 483–493, 2006.
- R. Kornowski, M. K. Hong, F. O. Tio, O. Bramwell, H. Wu, and M. B. Leon, “In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia,” Journal of the American College of Cardiology, vol. 31, no. 1, pp. 224–230, 1998.
- J. J. Li, J. Li, J. L. Nan et al., “Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects,” Medical Hypotheses, vol. 69, no. 5, pp. 1004–1009, 2007.
- A. Gaspardone and F. Versaci, “Coronary stenting and inflammation,” The American journal of cardiology., vol. 96, no. 12 A, pp. 65L–70L, 2005.
- J. J. Li, S. P. Nie, C. Y. Zhang, Z. Gao, X. Zheng, and Y. L. Guo, “Is inflammation a contributor for coronary stent restenosis?” Medical Hypotheses, vol. 68, no. 5, pp. 945–951, 2007.
- A. Dibra, J. Mehilli, S. Braun et al., “Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting,” The American Heart Journal, vol. 150, no. 2, pp. 344–350, 2005.
- A. Farb, G. Sangiorgi, A. J. Carter et al., “Pathology of acute and chronic coronary stenting in humans,” Circulation, vol. 99, no. 1, pp. 44–52, 1999.
- P. H. Grewe, T. Deneke, A. Machraoui, J. Barmeyer, and K. M. Müller, “Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen,” Journal of the American College of Cardiology, vol. 35, no. 1, pp. 157–163, 2000.
- C. Glover, X. Ma, Y. X. Chen et al., “Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation,” The American Heart Journal, vol. 144, no. 4, pp. 702–709, 2002.
- I. M. Chung, H. K. Gold, S. M. Schwartz, Y. Ikari, M. A. Reidy, and T. N. Wight, “Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment,” Journal of the American College of Cardiology, vol. 40, no. 12, pp. 2072–2081, 2002.
- F. G. Welt and C. Rogers, “Inflammation and restenosis in the stent era,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 11, pp. 1769–1776, 2002.
- A. Colombo and G. Sangiorgi, “The Monocyte: the key in the lock to reduce stent hyperplasia?” Journal of the American College of Cardiology, vol. 43, no. 1, pp. 24–26, 2004.
- F. R. Gong, X. Y. Cheng, S. F. Wang, Y. C. Zhao, Y. Gao, and H. B. Cai, “Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents,” Acta Biomaterialia, vol. 6, no. 2, pp. 534–546, 2010.
- J. H. Bräsen, A. Kivelä, K. Röser et al., “Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 11, pp. 1720–1726, 2001.
- N. A. Scott, “Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular responses to injury,” Advanced Drug Delivery Reviews, vol. 58, no. 3, pp. 358–376, 2006.
- T. Suzuki, G. Kopia, S. I. Hayashi et al., “Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model,” Circulation, vol. 104, no. 10, pp. 1188–1193, 2001.
- A. Blum, D. J. Schneider, B. E. Sobel, and H. L. Dauerman, “Endothelial dysfunction and inflammation after percutaneous coronary intervention,” The American Journal of Cardiology, vol. 94, no. 11, pp. 1420–1423, 2004.
- J. S. Li, R. Jabara, L. Pendyala et al., “Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents,” Journal of American College of Cardiology, vol. 1, no. 3, pp. 279–285, 2008.
- N. Werner, S. Junk, U. Laufs et al., “Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury,” Circulation research, vol. 93, no. 2, pp. e17–e24, 2003.
- D. Kong, L. G. Melo, A. A. Mangi et al., “Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells,” Circulation, vol. 109, no. 14, pp. 1769–1775, 2004.
- J. W. Kim, S. Y. Suh, C. U. Choi et al., “Six-month comparison of coronary endothelial dysfunction associated with Sirolimus-eluting stent versus paclitaxel-eluting stent,” Journal of American College of Cardiology, vol. 1, no. 1, pp. 65–71, 2008.
- J. W. Kim, H. S. Seo, J. H. Park et al., “A Prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent,” Journal of the American College of Cardiology, vol. 53, no. 18, pp. 1653–1659, 2009.
- B. Dominik and G. Peter, “Endothelial function: from vascular biology to clinical applications,” The American Journal of Cardiology, vol. 90, no. 10, pp. 40L–48L, 2002.
- E. Grube, S. Sonoda, F. Ikeno et al., “Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer,” Circulation, vol. 109, no. 18, pp. 2168–2171, 2004.